Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05303467 · ClinicalTrials.gov registry record · Phase 1
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
A Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 9
- Study locations
NCT05303467 is a Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 36 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (62% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT05303467, a Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 9
- Study locations
Study Summary
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions Studied
Interventions
- DEVICE TheraSphere GBM
Study Locations (9)
California
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
Alabama
- University of Alabama Birmingham - Birmingham
Florida
- Mayo Jacksonville - Jacksonville
Illinois
- Northwestern Univerity - Chicago
Maryland
- Johns Hopkins Interventional Radiology Center - Baltimore
Missouri
- Washington University School of Medicine - St Louis
New York
- Lenox Hill Hospital - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-07-30 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05303467
The ClinicalTrials.gov registry entry for NCT05303467 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (62% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which TheraSphere GBM is the first listed.
NCT05303467 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT05303467 about?
NCT05303467 is a clinical study titled "A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM". The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
What is the current status of trial NCT05303467?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-07-30. Estimated completion is 2027-01-31.
What conditions does trial NCT05303467 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Recurrent Glioblastoma.
What interventions are being tested in trial NCT05303467?
The interventions under investigation include: TheraSphere GBM (DEVICE).
Who is sponsoring clinical trial NCT05303467?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05303467 being conducted?
This trial has 9 study locations across Alabama, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.